Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 253 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Itching Clear all
Not yet recruiting Phase 2 Interventional

Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

NCT07620561
View directory record Official record
Conditions
Prurigo Nodularis (PN)
Interventions
Lebrikizumab
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Chula Vista, California • El Centro, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

NCT05287724
View directory record Official record
Conditions
Pruritus, Skin Disorder
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

NCT05265910
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale, Placebo
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 21, 2026, 9:00 PM EDT
Recruiting Early Phase 1 Interventional

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

NCT05649098
View directory record Official record
Conditions
Skin Diseases
Interventions
Dupilumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

NCT05133830
View directory record Official record
Conditions
Pruritus
Interventions
Obeticholic acid, Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 21, 2026, 9:00 PM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

NCT05978063
View directory record Official record
Conditions
Pruritus, Notalgia Paresthetica
Interventions
difelikefalin 2.0 mg tablets, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets, Placebo tablets
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

NCT03504852
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab 150 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Not applicable Interventional

The Effects of an Orally-Administered Probiotic on Vaginal Symptoms

NCT07829861
View directory record Official record
Conditions
Vaginal Odor
Interventions
Orally-administered probiotic, Placebo
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab low dose, secukinumab high dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

NCT01353976
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Foam 1%, Vehicle Foam
Drug · Other
Lead sponsor
AmDerma
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01309737
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

NCT05314621
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale, Saline nasal spray
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis

NCT01358240
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%, Placebo Cream
Drug · Other
Lead sponsor
AmDerma
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Fremont, California • Hockessin, Delaware • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 21, 2026, 9:00 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

NCT02842021
View directory record Official record
Conditions
Tinea Pedis
Interventions
S2G6T-1, S2G6T-2, S2G6T-3, S2G6T-4
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
San Diego, California • Clearwater, Florida • North Miami Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin

NCT02120833
View directory record Official record
Conditions
Eczema
Interventions
EpiCeram® Skin Barrier Emulsion, Colloidal Oatmeal Cream
Device · Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Months to 35 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501679
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

NCT03824912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Miami, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 21, 2026, 9:00 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

NCT00863395
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
skin biopsy
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View directory record Official record
Conditions
Chronic Pruritus, Atopic Dermatitis
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

NCT02654483
View directory record Official record
Conditions
Epidermolysis Bullosa, Pruritus
Interventions
VPD-737, Placebo
Drug · Other
Lead sponsor
Jean Yuh Tang
Other
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris

NCT00750152
View directory record Official record
Conditions
Tinea Cruris, Jock Itch
Interventions
NAFT-500, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 21, 2026, 9:00 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)

NCT00509275
View directory record Official record
Conditions
Tinea Pedis
Interventions
W0027, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Louisville, Kentucky • Warren, Michigan • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 9:00 PM EDT